BioTech/Drugs - Columbia, MO, US
Endevica Bio was formed in 2009 to create best in class peptide drug candidates with better safety and efficacy properties than other drugs in the same class. Endevica Bio's lead drug candidate is a peptide therapeutic for treating cachexia due to cancer and other chronic conditions. An IND is anticipated by the end of 2021 with a Phase 1 Clinical trial in 1st quarter 2022.
Outlook
Apache
WordPress.org
Google Font API
Mobile Friendly